Recombinant HIV Env polypeptides and their use

Patent metadata

Field	Value
Publication number	US-12281142-B2
Application number	US-202117335244-A
Country	US
Kind code	B2
Filing date	Jun 1, 2021
Priority date	Dec 1, 2018
Publication date	Apr 22, 2025
Grant date	Apr 22, 2025

Abstract

The present disclosure relates to recombinant HIV Env polypeptides and their use in the treatment and prevention of HIV/AIDS.

First claim

What is claimed is:

1. An isolated polypeptide comprising a variant HIV Env gp120 polypeptide,
wherein the variant HIV Env gp120 polypeptide comprises
a V1 loop comprising positions 131-154,
a V3 loop comprising positions 297-334, and
a β19 sheet comprising positions 413-419, and
wherein the V1 loop, positions 297-303 of the V3 loop, positions 319-334 of the V3 loop,
and the β19 sheet comprise:

(q)

(SEQ ID NO: 74)

CTNYAPKLLSNMRGEI, 

(SEQ ID NO: 77)

TRPNNNT,

(SEQ ID NO: 82)

FGDVLGHVRMAHCNIS, and 

(SEQ ID NO: 86)

SLILPCR,

respectively,

(r)

(SEQ ID NO: 75)

CTNYAPKLRSMMRGEI, 

(SEQ ID NO: 77)

TRPNNNT,

(SEQ ID NO: 81)

FGDVLGDVRMAHCNIS, and 

(SEQ ID NO: 86)

SLILPCR,

respectively,

(s)

(SEQ ID NO: 75)

CTNYAPKLRSMMRGEI, 

(SEQ ID NO: 77)

TRPNNNT,

(SEQ ID NO: 82)

FGDVLGHVRMAHCNIS, and 

(SEQ ID NO: 86)

SLILPCR,

respectively,

(t)

(SEQ ID NO: 75)

CTNYAPKLRSMMRGEI, 

(SEQ ID NO: 78)

TRPSNNT,

(SEQ ID NO: 82)

FGDVLGHVRMAHCNIS, and 

(SEQ ID NO: 86)

SLILPCR,

respectively,

(u)

(SEQ ID NO: 75)

CTNYAPKLRSMMRGEI, 

(SEQ ID NO: 78)

TRPSNNT,

(SEQ ID NO: 82)

FGDVLGHVRMAHCNIS, and 

(SEQ ID NO: 87)

SLILPCW,

respectively,

(v) 

(SEQ ID NO: 76)

CTNYAPNLRSDMRGEI, 

(SEQ ID NO: 77)

TRPNNNT,

(SEQ ID NO: 83)

FGDVLGDVDMAKCTIS, and 

(SEQ ID NO: 86)

SLILPCR,

respectively,

(w) 

(SEQ ID NO: 74)

CTNYAPKLLSNMRGEI, 

(SEQ ID NO: 77)

TRPNNNT,

(SEQ ID NO: 79)

TGDIIGDIRQAHCNVS, and 

(SEQ ID NO: 84)

SITLPCR,

respectively,

(x) 

(SEQ ID NO: 73)

CTNYAPNLLSNMRGEI 

(SEQ ID NO: 77)

TRPNNNT,

(SEQ ID NO: 80)

FGDIIGDIRMAHCNVS, and 

(SEQ ID NO: 85)

SIVLPCR,

respectively,

(y) 

(SEQ ID NO: 73)

CTNYAPNLLSNMRGEI, 

(SEQ ID NO: 77)

TRPNNNT,

(SEQ ID NO: 81)

FGDVLGDVRMAHCNIS, and 

(SEQ ID NO: 86)

SLILPCR,

respectively, or

(z) 

(SEQ ID NO: 75)

CTNYAPKLRSMMRGEI,

Assignees

• Int Aids Vaccine Initiative Inc
• Scripps Research Inst

Inventors

• Steichen Jon M
• Schief William R

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K39/21

  Retroviridae, e.g. equine infectious anemia virus · CPC title